The Official Journal of the Turkish Society Of Clinical Microbiology and Infectious Diseases (KLİMİK)

Treatment

Filter Newest Oldest Showing 1-10 of 10 results
Original Article / VOLUME 6, ISSUE 1, MARCH 2024

Knowledge and Attitudes of Patients About the Rational Use of Antibiotics

Pınar Korkmaz and others

Antimicrobial resistance can lead to morbidity and mortality in serious infections. Therefore, antimicrobial resistance has been accepted as a global public health problem in the 21st century. Unnecessary and excessive use of drugs is a serious problem in our country as well as in the rest of the world. Unnecessarily used drugs play an important role (...) Read More

Original Article / VOLUME 6, ISSUE 1, MARCH 2024

Individualized High Dose Intravenous Anakinra Treatment in Cancer Patients with COVID-19 Associated Cytokine Storm: A Retrospective Controlled Study

Ramazan Çakmak and Murat Bektaş

Coronavirus disease 2019 (COVID-19) is a potentially life-threatening disease caused by SARS-CoV-2. Clinical findings of COVID-19 are ranged from asymptomatic to severe pneumoniae, acute respiratory distress syndrome, multiorgan failure and death. A severe COVID-19 course is associated with a higher inflammatory state (cytokine storm) due to the excessive release (...) Read More

Review Article / VOLUME 5, ISSUE 4, DECEMBER 2023

New Treatment Options in Chronic Hepatitis B: How Close Are We to Cure?

Pınar Korkmaz and others

Hepatitis B virus (HBV) infection is the leading cause of chronic liver disease worldwide. HBV-infected patients are at risk of developing liver cirrhosis and hepatocellular carcinoma (HCC) for life. Today, pegylated interferon (Peg-IFN) and nucleos(t)ide analogues (NAs) are used in the treatment of patients with chronic hepatitis B (CHB). Both treatment options have limitations. Read More

Review Article / VOLUME 5, ISSUE 3, SEPTEMBER 2023

COVID-19: An Update on Epidemiology, Prevention and Treatment, September-2023

Serap Şimşek-Yavuz

After the World Health Organization (WHO) declared an end to COVID-19 as a global public health emergency on May 5, 2023, we have entered a new era in the pandemic, and most countries have already returned to normal life. This declaration was resulted from the 12-month downward trend of the pandemic, increased immunity due to the highly effective vaccines, decreased death rates, and decreased pressure on once overwhelmed (...) Read More

Original Article / VOLUME 5, ISSUE 2, JUNE 2023

COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study

Özge Kaya and others

Psoriasis, a chronic inflammatory disease, has a multifactorial etiology, including genetic, environmental, and behavioral factors. Since psoriasis is an immune system-mediated disease, immunosuppressive agents and biological treatments are frequently used in its treatment; however, these agents are known to increase the risk of infection. This situation (...) Read More

Original Article / VOLUME 4, ISSUE 4, DECEMBER 2022

Stenotrophomonas maltophilia Bacteremia: From Diagnosis to Treatment

Pınar Aysert-Yıldız and others

Stenotrophomonas maltophilia is an aerobic, non-fermentative, Gram-negative bacterium widespread in aquatic environments and soil. It has an inherent ability to adhere to abiotic surfaces and forms biofilms. It is usually considered to be a commensal and a low-grade pathogen. However, it can cause severe infections in the immunocompromised and debilitated (...) Read More

Case Report / VOLUME 2, ISSUE 1, APRIL 2020

Adverse Cardiac Events Related to Hydroxychloroquine Prophylaxis and Treatment of COVID-19

Rehile Zengin and others

Hydroxychloroquine is commonly used for the treatment of rheumatic diseases because of its antinflammatory effects. It is a 4-amino-quinoline that is widely used for the treatment purposes. The Scientific Advisory Board of Ministry of Health of Turkey for COVID-19 recommends HCQ for treatment and also for prophylactic use of COVID-19. Infectious Diseases Society of America (IDSA) suggested the HCQ but also warned Read More